The Journal of Informed Pharmacotherapy 2002;9:150.
Reviewer: James McCormack, B.Sc. (Pharm), Pharm. D.
Reviewer's email address: email@example.com
Reviewer's profession/specialty: Professor, Faculty of Pharmaceutical Sciences, University of British Columbia
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60. PubMed Citation
These investigators examined the benefit of treating hypertensive patients with nephropathy due to type 2 diabetes with irbesartan, amlodipine, or placebo.
1715 hypertensive patients with nephropathy due to type 2 diabetes.
Irbesartan 300 mg po daily, amlodipine 10 mg po daily or placebo.
|Doubling of SCr, ESRD (dialysis, renal transplant or Cr of at least 530 umoles/L) (%)||ESRD (%)||CV death, MI, CHF, stroke, limb amputation (%)||Serious adverse effects (%)|
|Relative Risk Reduction
(Irbesartan versus Placebo)
|Absolute Risk Reduction||6.4|
|NNT/NNH over 2.6 years||16|
NNT = numbers needed to treat, NNH = numbers needed to harm, NSS = not statistically significant
Mean arterial pressure was 3.3 mmHg lower in the drug groups - approximately 3/3 mmHg lower in the drug groups.
This study showed that an angiotensin-II-receptor blocker reduced the chance of the doubling of SCr, ESRD -dialysis, renal transplant or Cr of at least 530 by 6.4% compared to placebo in hypertensive type 2 diabetic patients with nephropathy over 2.6 years.
Copyright © 2002 by the Journal of Informed Pharmacotherapy. All rights reserved.